{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:06:14Z","timestamp":1788807974383,"version":"build-2803163510"},"reference-count":173,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1124\/pharmrev.124.000927","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T22:15:21Z","timestamp":1729030521000},"page":"1133-1158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair"],"prefix":"10.1016","volume":"76","author":[{"given":"Rina","family":"Aharoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Milo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Arnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.124.000927_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0022-510X(77)90220-9","article-title":"Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis","volume":"31","author":"Abramsky","year":"1977","journal-title":"J Neurol Sci"},{"key":"10.1124\/pharmrev.124.000927_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/2376-0389.1000e106","article-title":"Animal models of multiple sclerosis: imperfect but imperative","volume":"2","author":"Aharoni","year":"2015","journal-title":"J Mult Scler"},{"key":"10.1124\/pharmrev.124.000927_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2009.08.009","article-title":"Transplanted myogenic progenitor cells express neuronal markers in the CNS and ameliorate disease in experimental autoimmune encephalomyelitis","volume":"215","author":"Aharoni","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1358\/dnp.2009.22.6.1395253","article-title":"Linkage between immunomodulation neuroprotection and neurogenesis","volume":"22","author":"Aharoni","year":"2009","journal-title":"Drug News Perspect"},{"key":"10.1124\/pharmrev.124.000927_bib5","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1523\/JNEUROSCI.1859-05.2005","article-title":"Neurogenesis and neuroprotection induced by peripheral immuno-modulatory treatment of experimental autoimmune encephalomyelitis","volume":"25","author":"Aharoni","year":"2005","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.124.000927_bib6","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.3390\/ijms22115904","article-title":"Astrocytes in multiple sclerosis\u2014essential constituents with diverse multifaceted functions","volume":"22","author":"Aharoni","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pharmrev.124.000927_bib7","doi-asserted-by":"crossref","first-page":"19045","DOI":"10.1073\/pnas.0509438102","article-title":"The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice","volume":"102","author":"Aharoni","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib8","article-title":"Neuroprotective effect of glatiramer acetate on neurofilament light chain leakage and glutamate excess in an animal model of multiple sclerosis","volume":"22","author":"Aharoni","year":"2021","journal-title":"IJMS"},{"key":"10.1124\/pharmrev.124.000927_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577281","article-title":"Glatiramer acetate increases T- and B-regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis","volume":"345","author":"Aharoni","year":"2020","journal-title":"J Neuroimmuno"},{"key":"10.1124\/pharmrev.124.000927_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jneuroim.2010.04.022","article-title":"Glatiramer acetate reduces Th-17 inflammation and induces regulatory T-cells in the CNS of mice with relapsing-remitting or chronic EAE","volume":"225","author":"Aharoni","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib11","doi-asserted-by":"crossref","first-page":"11358","DOI":"10.1073\/pnas.0804632105","article-title":"Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis","volume":"105","author":"Aharoni","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1124\/jpet.106.103192","article-title":"Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease","volume":"318","author":"Aharoni","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.124.000927_bib13","doi-asserted-by":"crossref","first-page":"14157","DOI":"10.1073\/pnas.2336171100","article-title":"Glatiramer acetate-specific T cells in the brain express T helper 2\/3 cytokines and brain-derived neurotrophic factor in situ","volume":"100","author":"Aharoni","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jneuroim.2016.10.015","article-title":"Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis","volume":"301","author":"Aharoni","year":"2016","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.expneurol.2012.11.004","article-title":"Magnetic resonance imaging characterization of different experimental autoimmune encephalomyelitis models and the therapeutic effect of glatiramer acetate","volume":"240","author":"Aharoni","year":"2013","journal-title":"Exp Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib16","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1038\/s41598-019-40713-4","article-title":"Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate","volume":"9","author":"Aharoni","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/pharmrev.124.000927_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.imlet.2007.07.009","article-title":"The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells","volume":"112","author":"Aharoni","year":"2007","journal-title":"Immunol Lett"},{"key":"10.1124\/pharmrev.124.000927_bib18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1073\/pnas.96.2.634","article-title":"Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking","volume":"96","author":"Aharoni","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/00007890-200108270-00007","article-title":"Copolymer 1 inhibits manifestations of graft rejection","volume":"72","author":"Aharoni","year":"2001","journal-title":"Transplantation"},{"key":"10.1124\/pharmrev.124.000927_bib20","doi-asserted-by":"crossref","first-page":"11472","DOI":"10.1073\/pnas.97.21.11472","article-title":"Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1","volume":"97","author":"Aharoni","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib21","doi-asserted-by":"crossref","first-page":"10821","DOI":"10.1073\/pnas.94.20.10821","article-title":"Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis","volume":"94","author":"Aharoni","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0165-5728(98)00166-0","article-title":"Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1","volume":"91","author":"Aharoni","year":"1998","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaut.2011.06.003","article-title":"Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate","volume":"37","author":"Aharoni","year":"2011","journal-title":"J Autoimmun"},{"key":"10.1124\/pharmrev.124.000927_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.intimp.2004.09.007","article-title":"Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection","volume":"5","author":"Aharoni","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"10.1124\/pharmrev.124.000927_bib25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1474-4422(22)00471-9","article-title":"Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy","volume":"22","author":"Aloisi","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib26","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.4049\/jimmunol.1801235","article-title":"Glatiramer acetate stimulates regulatory B cell functions","volume":"202","author":"Amrouche","year":"2019","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib27","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1073\/pnas.0530191100","article-title":"Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis","volume":"100","author":"Angelov","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-2478(96)02506-0","article-title":"The development of Cop 1 (Copaxone@), an innovative drug for the treatment of multiple sclerosis: personal reflections","volume":"50","author":"Arnon","year":"1996","journal-title":"Immunol Lett"},{"key":"10.1124\/pharmrev.124.000927_bib29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1146\/annurev-immunol-102319-103410","article-title":"Meningeal immunity and its function in maintenance of the central nervous system in health and disease","volume":"38","author":"Alves de Lima","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/WCO.0000000000001045","article-title":"Microglia in multiple sclerosis\u2014pathogenesis and imaging","volume":"35","author":"Airas","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jneuroim.2005.07.001","article-title":"Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate","volume":"167","author":"Azoulay","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib32","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/ana.20016","article-title":"Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion","volume":"55","author":"Barnett","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1600-0463.2011.02794.x","article-title":"Experimental autoimmune encephalomyelitis\u2014achievements and prospective advances","volume":"119","author":"Batoulis","year":"2011","journal-title":"APMIS"},{"key":"10.1124\/pharmrev.124.000927_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.coi.2011.08.005","article-title":"T(H)17 cytokines in autoimmune neuro-inflammation","volume":"23","author":"Becher","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib35","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.immuni.2016.10.026","article-title":"GM-CSF: from growth factor to central mediator of tissue inflammation","volume":"45","author":"Becher","year":"2016","journal-title":"Immunity"},{"key":"10.1124\/pharmrev.124.000927_bib36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jneuroim.2010.10.031","article-title":"Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate","volume":"232","author":"Begum-Haque","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jneuroim.2009.11.016","article-title":"Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis","volume":"219","author":"Begum-Haque","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jneuroim.2008.07.018","article-title":"Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis","volume":"204","author":"Begum-Haque","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib39","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.mehy.2010.09.015","article-title":"Glatiramer acetate (GA, copolymer-1) an hypothetical treatment option for Rett syndrome","volume":"76","author":"Ben-Zeev","year":"2010","journal-title":"Med Hypotheses"},{"key":"10.1124\/pharmrev.124.000927_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00019052-200106000-00003","article-title":"Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences","volume":"14","author":"Bjartmar","year":"2001","journal-title":"Curr Opin Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib410","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1124\/pharmrev.124.000927_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ana.410110314","article-title":"Multiple sclerosis: trial of a synthetic polypeptide","volume":"11","author":"Bornstein","year":"1982","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJM198708133170703","article-title":"A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis","volume":"317","author":"Bornstein","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1212\/WNL.41.4.533","article-title":"A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis","volume":"41","author":"Bornstein","year":"1991","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib44","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.124.000927_bib45","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","article-title":"Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.smim.2019.101323","article-title":"IL-10-producing regulatory B cells and plasmocytes: molecular mechanisms and disease relevance","volume":"44","author":"Cerqueira","year":"2019","journal-title":"Semin Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ane.13553","article-title":"Central vein sign: A putative diagnostic marker for multiple sclerosis","volume":"145","author":"Chaaban","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1124\/pharmrev.124.000927_bib48","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-510X(03)00177-1","article-title":"Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor","volume":"215","author":"Chen","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1124\/pharmrev.124.000927_bib49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ncl.2023.06.008","article-title":"Recent advances in diagnostic, prognostic, and disease-monitoring biomarkers in multiple sclerosis","volume":"42","author":"Chertcoff","year":"2024","journal-title":"Neurol Clin"},{"key":"10.1124\/pharmrev.124.000927_bib50","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2019.02.014","article-title":"Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation","volume":"25","author":"Cohen","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1124\/pharmrev.124.000927_bib51","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.124.000927_bib52","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.124.000927_bib53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ana.22316","article-title":"Phase III dose-comparison study of glatiramer acetate for multiple sclerosis","volume":"69","author":"Comi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib54","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","volume":"18","author":"Comi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib55","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.124.000927_bib56","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Brit J Pharmacol"},{"key":"10.1124\/pharmrev.124.000927_bib57","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.2174\/092986711795496881","article-title":"Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment","volume":"18","author":"De Santi","year":"2011","journal-title":"Curr Med Chem"},{"issue":"Suppl 4","key":"10.1124\/pharmrev.124.000927_bib58","article-title":"Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis","volume":"58","author":"Dhib-Jalbut","year":"2002","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib59","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1172\/JCI8970","article-title":"Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis","volume":"105","author":"Duda","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.124.000927_bib60","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/glia.23304","article-title":"Astrocyte disruption of neurovascular communication is linked to cortical damage in an animal model of multiple sclerosis","volume":"66","author":"Eilam","year":"2018","journal-title":"Glia"},{"key":"10.1124\/pharmrev.124.000927_bib61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000109933","article-title":"Natalizumab: targeting alpha4-integrins in multiple sclerosis","volume":"5","author":"Engelhardt","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1124\/pharmrev.124.000927_bib62","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1212\/WNL.57.4.731","article-title":"Glatiramer acetate reduces the proportion of new MS lesions evolving into \u201cblack holes.\u201d","volume":"57","author":"Filippi","year":"2001","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib63","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1177\/13524585221094239","article-title":"Early versus delayed treatment with glatiramer acetate: analysis of up to 27\u2009years of continuous follow-up in a US open-label extension study","volume":"28","author":"Ford","year":"2022","journal-title":"Mult Scler"},{"key":"10.1124\/pharmrev.124.000927_bib64","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1073\/pnas.91.11.4872","article-title":"Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells\u2013specificity and promiscuity","volume":"91","author":"Fridkis-Hareli","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib65","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"key":"10.1124\/pharmrev.124.000927_bib66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/glia.22632","article-title":"Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate","volume":"62","author":"From","year":"2014","journal-title":"Glia"},{"key":"10.1124\/pharmrev.124.000927_bib67","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMra052130","article-title":"Multiple sclerosis\u2014the plaque and its pathogenesis","volume":"354","author":"Frohman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib68","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0301-0082(95)80008-V","article-title":"Migrant studies in multiple sclerosis","volume":"47","author":"Gale","year":"1995","journal-title":"Prog Neurobiol"},{"key":"10.1124\/pharmrev.124.000927_bib69","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-0102(03)00217-7","article-title":"Axonal damage is reduced following glatiramer acetate treatment in C57\/bl mice with chronic-induced experimental autoimmune encephalomyelitis","volume":"47","author":"Gilgun-Sherki","year":"2003","journal-title":"Neurosci Res"},{"key":"10.1124\/pharmrev.124.000927_bib70","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib71","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib72","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.autrev.2009.02.013","article-title":"Myelin peptides in multiple sclerosis","volume":"8","author":"Grau-L\u00f3pez","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1124\/pharmrev.124.000927_bib73","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.0105-2896.2005.00240.x","article-title":"Multiple sclerosis","volume":"204","author":"Hafler","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1124\/pharmrev.124.000927_bib74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/WNP.0000000000000723","article-title":"Multimodal evoked potentials as candidate prognostic and response biomarkers in clinical trials of multiple sclerosis","volume":"38","author":"Hardmeier","year":"2021","journal-title":"J Clin Neurophysiol"},{"key":"10.1124\/pharmrev.124.000927_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"10.1124\/pharmrev.124.000927_bib76","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib77","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib78","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1124\/pharmrev.124.000927_bib79","article-title":"Freedom from disease activity in multiple sclerosis","volume":"74","author":"Havrdova","year":"2010","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib80","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/1352458508089411","article-title":"Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid","volume":"14","author":"Hestvik","year":"2008","journal-title":"Mult Scler"},{"key":"10.1124\/pharmrev.124.000927_bib81","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib82","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1073\/pnas.0502187102","article-title":"Induction of CD4\u00feCD25\u00fe regulatory T cells by copolymer-I through activation of transcription factor Foxp3","volume":"102","author":"Hong","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib83","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tins.2023.11.005","article-title":"Toward identifying key mechanisms of progression in multiple sclerosis","volume":"47","author":"Husseini","year":"2024","journal-title":"Trends Neurosci"},{"key":"10.1124\/pharmrev.124.000927_bib84","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000200962","article-title":"Association of multiple sclerosis prevalence with sociodemographic, health systems, and lifestyle factors on a national and regional level","volume":"99","author":"Hwang","year":"2022","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib85","first-page":"655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial","volume":"76","year":"1993","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib86","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","year":"2019","journal-title":"Science"},{"key":"10.1124\/pharmrev.124.000927_bib87","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41586-023-06250-x","article-title":"Locus for severity implicates CNS resilience in progression of multiple sclerosis","volume":"619","year":"2023","journal-title":"Nature"},{"key":"10.1124\/pharmrev.124.000927_bib88","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/jamaneurol.2014.1472","article-title":"The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis","volume":"71","author":"Ireland","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib89","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2023","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.124.000927_bib91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clim.2007.05.020","article-title":"CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis","volume":"125","author":"Jee","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib92","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib93","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.expneurol.2009.10.015","article-title":"B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis","volume":"221","author":"Kala","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib94","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1001\/archneur.59.10.1572","article-title":"Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype","volume":"59","author":"Kalkers","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib95","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.124.000927_bib96","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib97","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib98","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib99","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1172\/JCI200214380","article-title":"Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis","volume":"109","author":"Karandikar","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.124.000927_bib100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jneuroim.2010.01.009","article-title":"Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy","volume":"220","author":"Karussis","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib101","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029025","article-title":"Effector T cells in multiple sclerosis","volume":"8","author":"Kaskow","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1124\/pharmrev.124.000927_bib102","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1084\/jem.20050011","article-title":"Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion","volume":"201","author":"Kawakami","year":"2005","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.124.000927_bib103","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1191\/1352458505ms1234oa","article-title":"Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis","volume":"11","author":"Khan","year":"2005","journal-title":"Mult Scler"},{"key":"10.1124\/pharmrev.124.000927_bib104","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.1073\/pnas.97.13.7446","article-title":"T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies","volume":"97","author":"Kipnis","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib105","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00401-009-0591-3","article-title":"The cuprizone animal model: new insights into an old story","volume":"118","author":"Kipp","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1124\/pharmrev.124.000927_bib106","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/imr.12169","article-title":"Regulatory T cells in autoimmune neuroinflammation","volume":"259","author":"Kleinewietfeld","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1124\/pharmrev.124.000927_bib107","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200939568","article-title":"EAE: an immunologist's magic eye","volume":"39","author":"Krishnamoorthy","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib108","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib109","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1093\/brain\/awt220","article-title":"Epidemiology in multiple sclerosis: a pilgrim's progress","volume":"136","author":"Kurtzke","year":"2013","journal-title":"Brain"},{"key":"10.1124\/pharmrev.124.000927_bib110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib111","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/1352458519872751","article-title":"Optical coherence tomography and multiple sclerosis: update on clinical application and role in clinical trials","volume":"26","author":"Lambe","year":"2020","journal-title":"Mult Scler"},{"key":"10.1124\/pharmrev.124.000927_bib112","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jns.2008.04.003","article-title":"Mechanisms of inflammation induced tissue injury in multiple sclerosis","volume":"274","author":"Lassmann","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1124\/pharmrev.124.000927_bib113","article-title":"Multiple sclerosis pathology","volume":"8","author":"Lassmann","year":"2019","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1124\/pharmrev.124.000927_bib114","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jneuroim.2006.11.009","article-title":"CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease","volume":"183","author":"Laurie","year":"2007","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0301-0082(03)00019-4","article-title":"Neurotrophin secretion: current facts and future prospects","volume":"69","author":"Lessmann","year":"2003","journal-title":"Prog Neurobiol"},{"key":"10.1124\/pharmrev.124.000927_bib116","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P","volume":"46","author":"Li","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib117","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0014-2999(97)01509-4","article-title":"Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma","volume":"342","author":"Li","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.124.000927_bib118","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2020.08.012","article-title":"Astrocyte crosstalk in CNS inflammation","volume":"108","author":"Linnerbauer","year":"2020","journal-title":"Neuron"},{"key":"10.1124\/pharmrev.124.000927_bib119","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/eji.200737398","article-title":"T cell independent mechanism for copolymer-1-induced neuroprotection","volume":"37","author":"Liu","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib120","series-title":"Neuroinflammation","first-page":"81","article-title":"Neuroimaging of multiple sclerosis: an update","author":"Lopez-Soriano","year":"2011"},{"key":"10.1124\/pharmrev.124.000927_bib121","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib122","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib123","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib124","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa1100648","article-title":"Inflammatory cortical demyelination in early multiple sclerosis","volume":"365","author":"Lucchinetti","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/35016083","article-title":"Induction of neurogenesis in the neocortex of adult mice","volume":"405","author":"Magavi","year":"2000","journal-title":"Nature"},{"key":"10.1124\/pharmrev.124.000927_bib126","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2353\/ajpath.2006.060159","article-title":"Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model o multiple sclerosis: a comparative study","volume":"169","author":"Maier","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1124\/pharmrev.124.000927_bib127","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nm1202","article-title":"Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis","volume":"11","author":"McMahon","year":"2005","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.124.000927_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2009.11.010","article-title":"Multiple sclerosis: geoepidemiology, genetics and the environment","volume":"9","author":"Milo","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.124.000927_bib129","volume":"100","author":"Miller","year":"2023","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib130","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/14656566.2015.1002769","article-title":"Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs","volume":"16","author":"Milo","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/pharmrev.124.000927_bib411","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3325\/cmj.2019.60.87","article-title":"Therapies for multiple sclerosis targeting B cells","volume":"60","author":"Milo","year":"2019","journal-title":"Croat Med J"},{"key":"10.1124\/pharmrev.124.000927_bib131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib132","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib133","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1073\/pnas.97.13.7452","article-title":"Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells","volume":"97","author":"Neuhaus","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib134","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0039.1991.tb02029.x","article-title":"HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation","volume":"38","author":"Olerup","year":"1991","journal-title":"Tissue Antigens"},{"key":"10.1124\/pharmrev.124.000927_bib136","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-2377-12-95","article-title":"TH1\/TH2 cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab","volume":"12","author":"Oreja-Guevara","year":"2012","journal-title":"BMC Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib137","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028951","article-title":"Genetics of multiple sclerosis: an overview and new directions","volume":"8","author":"Patsopoulos","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1124\/pharmrev.124.000927_bib138","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","author":"Paty","year":"1993","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib139","doi-asserted-by":"crossref","first-page":"13211","DOI":"10.1073\/pnas.192314199","article-title":"Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice","volume":"99","author":"Picard-Riera","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib140","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib141","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-pathol-011811-132443","article-title":"Pathology of demyelinating diseases","volume":"7","author":"Popescu","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"10.1124\/pharmrev.124.000927_bib142","first-page":"1498","article-title":"Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"76","year":"1998","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.124.000927_bib143","article-title":"Smouldering lesion in MS: microglia, lymphocytes and pathobiochemical mechanisms","volume":"24","author":"Pukoli","year":"2023","journal-title":"IJMS"},{"key":"10.1124\/pharmrev.124.000927_bib144","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T cell subsets and their signature cytokines in autoimmune and inflammatory diseases","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine"},{"key":"10.1124\/pharmrev.124.000927_bib145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1084\/jem.58.1.39","article-title":"Observations on attempts to produce acute disseminated encephalomyelitis in monkeys","volume":"58","author":"Rivers","year":"1933","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.124.000927_bib146","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1474-4422(06)70410-0","article-title":"Secondary progressive multiple sclerosis: current knowledge and future challenges","volume":"5","author":"Rovaris","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.909275","article-title":"Innate lymphoid cells\u2014neglected players in multiple sclerosis","volume":"13","author":"Sadeghi Hassanabadi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib148","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1073\/pnas.93.10.5061","volume":"93","author":"Schlegel","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib412","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple sclerosis: time for early treatment with high-efficacy drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib149","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1177\/13524585231205708","article-title":"Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: final safety and efficacy results from the phase 3 EVOLVE-MS-1 study","volume":"29","author":"Singer","year":"2023","journal-title":"Mult Scler"},{"key":"10.1124\/pharmrev.124.000927_bib150","doi-asserted-by":"crossref","first-page":"17992","DOI":"10.1073\/pnas.0909607106","article-title":"Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate","volume":"106","author":"Skihar","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.124.000927_bib151","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.124.000927_bib152","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/nprot.2006.284","article-title":"Passive induction of experimental allergic encephalomyelitis","volume":"1","author":"Stromnes","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1124\/pharmrev.124.000927_bib153","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000004977","article-title":"Cognition in multiple sclerosis: state of the field and priorities for the future","volume":"90","author":"Sumowski","year":"2018","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.124.000927_bib154","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/eji.1830010406","article-title":"Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide","volume":"1","author":"Teitelbaum","year":"1971","journal-title":"Eur J Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib155","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/PL00000576","article-title":"Copolymer 1: from basic research to clinical application","volume":"53","author":"Teitelbaum","year":"1997","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/pharmrev.124.000927_bib156","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib157","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/ijms18030504","article-title":"The diverse roles of microglia in the neurodegenerative aspects of central nervous system (CNS) autoimmunity","volume":"18","author":"Thompson","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1124\/pharmrev.124.000927_bib158","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11481-009-9179-x","article-title":"Neuropathogenesis of Theiler's murine encephalomyelitis virus infection, an animal model for multiple sclerosis","volume":"5","author":"Tsunoda","year":"2010","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1124\/pharmrev.124.000927_bib159","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.4049\/jimmunol.170.9.4483","article-title":"Glatiramer acetate (copolymer-1, Copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells","volume":"170","author":"Vieira","year":"2003","journal-title":"J Immunol"},{"key":"10.1124\/pharmrev.124.000927_bib160","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J Exp Med"},{"key":"10.1124\/pharmrev.124.000927_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.1024058","article-title":"Chronic experimental autoimmune encephalomyelitis is an excellent model to study neuroaxonal degeneration in multiple sclerosis","volume":"15","author":"Voskuhl","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1124\/pharmrev.124.000927_bib162","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib163","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/brain\/awh163","article-title":"Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo","volume":"127","author":"Weber","year":"2004","journal-title":"Brain J Neurol"},{"key":"10.1124\/pharmrev.124.000927_bib164","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nm1620","article-title":"Type II monocytes modulate T cell-mediated central nervous system autoimmune disease","volume":"13","author":"Weber","year":"2007","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.124.000927_bib165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"key":"10.1124\/pharmrev.124.000927_bib166","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/08916934.2017.1281914","article-title":"B cells in multiple sclerosis","volume":"50","author":"Wekerle","year":"2017","journal-title":"Autoimmunity"},{"key":"10.1124\/pharmrev.124.000927_bib167","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ncl.2010.12.009","article-title":"The immunopathophysiology of multiple sclerosis","volume":"29","author":"Wu","year":"2011","journal-title":"Neurol Clin"},{"key":"10.1124\/pharmrev.124.000927_bib168","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jnr.24509","article-title":"Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process","volume":"98","author":"Yazdi","year":"2020","journal-title":"J Neurosci Res"},{"key":"10.1124\/pharmrev.124.000927_bib169","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2010.06.014","article-title":"Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: role of IGF-2","volume":"227","author":"Zhang","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1124\/pharmrev.124.000927_bib170","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/brain\/awf252","article-title":"Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor","volume":"125","author":"Ziemssen","year":"2002","journal-title":"Brain J Neurol"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972401651X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003169972401651X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.124.000927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:11:11Z","timestamp":1739877071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003169972401651X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":173,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S003169972401651X"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.124.000927","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.124.000927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}